High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice?
The development of high responding inhibitors is an increasingly recognized complication of mild Haemophilia. Inhibitors tend to develop in adolescence and adulthood and this is frequently preceded by high-intensity factor replacement therapy. We report two patients with mild Haemophilia who developed high responding inhibitors after continuous infusion with recombinant factor VIII (Kogenate) as prophylaxis for surgery. We discuss whether recent changes in clinical practice could be responsible for the apparent increase in high responding inhibitors in mild Haemophilia.
White
B
B
National Centre for Inherited Coagulation Disorders, St James's Hospital, Dublin; and Trinity College Dublin, Ireland.
Cotter
M
M
Byrne
M
M
O'Shea
E
E
Smith
O P
OP
D000328:Adult; D005169:Factor VIII / Q000008:administration & dosage* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006467:Hemophilia A / Q000378:metabolism* / Q000601:surgery; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007263:Infusions, Parenteral / Q000009:adverse effects; D007518:Isoantibodies / Q000009:adverse effects / Q000097:blood; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D007518:Isoantibodies; D011994:Recombinant Proteins; D005169:Factor VIII